Being bio-reactive

Acting and reacting in life science biotechnologies

Powered by
tebu-bio
  • Facebook
  • Google+
  • Linkedin
  • Twitter
  • YouTube
Acting & reacting in life sciences and biotechnologies  
  • Research areas
    • ADME-Tox
    • Biomarkers
    • Cell Biology and Signalling
    • Cell Sourcing – Cell Culture Technologies
    • Drug Discovery
    • Gene Expression – Molecular Biology
    • Stem Cells
    • Supplying Discovery Tools
  • About us
  • Contact us
You are here: Home / Archives for Tim-3

Cancer Immunotherapy – Investigate the TIGIT/CD226 Pathway

11/08/2016 By Ali El Baya, PhD Leave a Comment

TIGIT (VSTM3)/CD226 and CD28/CTLA-4 Pathway - Being bioreactive

Fig 1: TIGIT (VSTM3)/CD226 and CD28/CTLA-4 Pathway

Over the past months, we have released a number of posts introducing inhibitor screening assays intended to investigate immuno checkpoint protein interactions, such as PD-1/PD-L1/PD-L2;  B7-1/CD28, B7-1/CTLA4;  BLTA/HVEM, CD47/SIRPα; GITR/GITRL and many others – for an overview, you might like to read 9 pathway-specific screening assays in Immunotherapy.

Today, I’d like to concentrate on the TIGIT/CD226 pathway, because it acts through a novel mechanism to regulate CD8+ T cell functions within the tumour microenvironment. [Read more…]

Filed Under: Drug Discovery Tagged With: Cancer immunotherapy, CD112, CD155, CD226, DNAM-1, Lag-3, Nectin-2, PD-1, PVR, TIGIT, Tim-3, VSTM3

Top Posts & Pages

  • HeLa cells: Origin of this important cell line in life science research
  • From RUO to IVD - the acronym guide to reagents' intended use
  • Differentiate between Apoptosis, Necroptosis, Autophagy & Ferroptosis
  • What to do with Microsome Stable, Low-Turnover Compounds
  • AAV - advantages for Gene delivery in vivo

Follow us on Twitter

My Tweets

Copyright © 2018 · being bioreactive's blog